Search results
Results from the WOW.Com Content Network
ViewRay (VRAY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
The consensus price target hints at a 38.4% upside potential for ViewRay (VRAY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings ...
ViewRay (VRAY) delivered earnings and revenue surprises of -6.67% and 2.76%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
ViewRay Inc (NASDAQ:VRAY), a medical equipment company based in United States, received a lot of attention from a substantial price movement on the NasdaqGM in the over the last fewRead More...
An initial public offering (IPO) or stock launch is a public offering in which shares of a company are sold to institutional investors [1] and usually also to retail (individual) investors. [2] An IPO is typically underwritten by one or more investment banks , who also arrange for the shares to be listed on one or more stock exchanges .
Image-guided radiation therapy (IGRT) is the process of frequent imaging, during a course of radiation treatment, used to direct the treatment, position the patient, and compare to the pre-therapy imaging from the treatment plan. [1]
In 1989, S.G Warburg pharmaceutical analysts Viren Mehta and Samuel Isaly founded Mehta & Isaly, a money-management and research firm. This was the predecessor firm to OrbiMed.
ViewRay (VRAY) closed at $7.39 in the latest trading session, marking a -0.4% move from the prior day.